SUMMER FORUM 2020
Should SGLT2 inhibitors be part of standard of care for patients with insufficiently controlled type 2 diabetes
Session Summary Statement: Not all patients with type 2 diabetes a…
Summer Forum part 2 (7/7) Nothing about us without us connecting with your diabetes patients to achieve shared goals
Five principles have been recognised as part of the next phase of …
Summer Forum part 2 (6/7) Nothing about us without us – How to keep the patients at the heart of everything we do
Five principles have been recognised as part of the next phase of …
Summer Forum part 2 (5/7) The challenges of Diabetes Service Management under COVID19
The panel will focus on accelerating the return to near-normal lev…
Summer Forum Part 2 (4/5) Question time: Long Covid & Kidney Health
Our panel answered your questions relating to Long Covid and Kidne…
Summer Forum Part 2 (3/5) Long COVID – The impact on the heart, the lungs, and the brain
Long COVID – The impact on the heart, the lungs, and the brain of …
Summer Forum Part 2 (2/5) The Kidney as a canary
Key learning outcomes: Renal impairment is the single strongest pr…
Summer Forum Part 2 (1/5): The kidney as a filter
The kidney as a filter – Diabetic Nephropathy & Challenges of …
Summer Forum 6/6 Your questions answered
The DPC Summer Forum - ADA into practice has deciphered the main o…
Hidden Burden of Hyperkalemia – Panel session
Summer Forum 5/5
Hyperkalaemia is a common diagnosis. Fortunat…
Summer Forum 4/5: DAPA-HF – ADA UPDATE AND PRESCRIBING IN PRACTICE – PANEL
This live webinar will cover key take-home messages from the recen…
Summer Forum 3/5 - GLP1 ADA Round up
This live webinar will cover key take-home messages from the recen…
Summer Forum 2/5: SGLT2S VERTIS - A CLASS EFFECT
This live webinar will covered key take-home messages from the rec…